---
url: "https://dfylegitscript.com/blog/marketing-compounded-glp-1-products-without-a-misbranding-problem"
title: "Marketing compounded GLP-1 products without writing your own warning letter"
description: "Every FDA warning letter issued to a telehealth or compounding company over compounded GLP-1 marketing turns on how the product was described, which makes the sentence under the product photograph the single most reviewed asset a weight management brand owns."
published: "2025-11-08T10:36:07+00:00"
modified: "2026-02-23T08:01:23+00:00"
---

# Marketing compounded GLP-1 products without writing your own warning letter

Every FDA warning letter issued to a telehealth or compounding company over compounded GLP-1 marketing turns on how the product was described, which makes the sentence under the product photograph the single most reviewed asset a weight management brand owns.

## Key takeaways

- Enforcement in this category turns on how the product was described, which makes the sentence under the product photograph the most reviewed asset the brand owns.
- Four sentences do most of the damage: calling a compounded preparation approved, comparing it to the brand-name drug, promising a weight outcome, and calling it safe and effective.
- What is sayable is what is true of a compounded preparation prescribed for an individual patient, described as compounded and never as an approved product.
- Personalised is a claim rather than a softener, because it asserts that something about the preparation was decided for the patient receiving it.
- Fix the sentence in every channel it reached: the ad, the landing page, the quiz result, the email sequence and the leaflet in the box.

Compounded semaglutide and tirzepatide are the most heavily scrutinised
marketing category in telehealth, and the scrutiny is documented. We maintain an
[index of every FDA warning letter](/research/glp-1-compounding-warning-letters)
issued to telehealth and compounding companies over compounded GLP-1 marketing,
built row by row from the letters themselves rather than from summaries. The
current count, the enforcement rounds and the tally for each violation are all
on that page.

What is striking is not the volume. It is the uniformity. Misbranding is cited
throughout the series, and behind it come the claim that a compounded drug is
FDA-approved, the comparison to the brand-name product, and the promise of
safety or effectiveness.

These are not exotic failures. They are four sentences that a copywriter writes
without thinking, and they are the same sentences that stall a certification
review.

## The four sentences

**"FDA-approved semaglutide."** The compounded preparation is not an approved
product. Approval attaches to a specific product from a specific manufacturer,
and a compounded preparation containing the same active ingredient does not
inherit it. Neither does "made with FDA-approved ingredients", which is a
sentence engineered to be read as the claim it disclaims.

**"The same as the brand-name drug, for less."** Comparison is where the largest
number of these letters land after the approval claim. A compounded preparation
has not been shown to be equivalent to the approved product in safety,
effectiveness or quality, because nobody has reviewed it for that. Comparative
pricing framed against a named brand carries the equivalence implication even
where the text does not state it.

**"Lose up to X pounds."** An effectiveness claim about a product that has not
been reviewed for effectiveness. Borrowing trial results from the approved drug
and presenting them for a compounded preparation is the most common version, and
it is the version that is hardest to argue was accidental.

**"Safe and effective."** Both halves are regulatory terms of art here, and both
describe a review that has not happened for a compounded product.

## What you can say

This is the part that gets lost in compliance advice that is all prohibition.
Plenty is sayable, and it converts.

You can describe what the preparation is, including its active ingredient. You
can be clear that it is compounded and prepared by a named pharmacy under a
prescription for the individual patient. You can describe your clinical model
honestly: who prescribes, what the consultation involves, what follow-up looks
like, how dosing is supervised.

You can talk about service. Speed of consultation, quality of clinical support,
what happens if the patient has a question at eleven at night, how cancellation
works. In a category where the product is broadly similar between competitors,
service is the honest differentiator and it is entirely unrestricted.

And you can be plain about what the product is not. Brands consistently
underestimate how well that converts with the specific customer who is
hesitating because they suspect they are being sold something dressed up.

## The word "personalised" deserves its own paragraph

Personalised dosing is a claim, and the warning letter dataset includes it as a
category of its own. Where a compounded preparation is presented as tailored to
the individual, the presentation has to match what is actually happening
clinically. If the personalisation is a prescriber choosing between three
standard strengths, describing it as a bespoke formulation is a claim about the
product rather than about the service.

The same caution applies to added ingredients presented as enhancements. Framing
an additive as improving outcomes is an effectiveness claim about a preparation
nobody has studied.

## Where the claims actually live

The audit that matters covers more than the product page. In practice the
offending sentence turns up in:

- Paid ad copy and the headline of the landing page it points at.
- The quiz result screen, which is where "your personalised plan" tends to live.
- Email sequences, particularly the abandoned-cart and win-back flows written
  eighteen months ago by somebody who has left.
- Affiliate and influencer content driving into your funnel.
- Customer support macros, which is where a support agent reassures a nervous
  customer with a comparison to the brand-name drug in writing.

The last two are the ones brands forget, and both are discoverable.

## Doing this once, properly

Write a claims allowlist. One page per product: what the preparation is, what the
pharmacy relationship is, what may be said, what may not be said, and the exact
approved phrasing for the two or three things everybody wants to say. Get it
signed off by whoever owns clinical. Give it to every copywriter, agency and
affiliate you work with.

Then sweep everything that is already live against it, including the channels
above.

That sweep is the largest single piece of preparation for a certification
application in this category, and it is the reason applications in weight
management take longer than their operators expect. It is also work that pays
for itself independently of certification, because
[what disqualifies an application](/blog/what-disqualifies-a-legitscript-application)
and what draws a warning letter are, in this category, very nearly the same list.

## Rewriting the four sentences

The useful exercise is not deleting the claim, it is finding what the claim was
doing and meeting that need honestly.

**The approval claim was doing reassurance.** The patient wants to know this is
not something dubious. Reassure them with the things that are true: a named
prescriber, a named pharmacy, a real clinical review, a route back to a
clinician.

**The comparison was doing price justification.** Compare against your own
plans instead. Explain what is included, what the consultation covers, what
happens if a prescriber declines. Comparison against your own offer is
unrestricted and it converts better than an implication the reader half suspects.

**The outcome claim was doing motivation.** Motivation can come from the process
rather than the product: what the first month looks like, how dosing is
supervised, what support exists when something is difficult.

**The safety claim was doing objection handling.** Handle the objection directly.
Say what the preparation is, say what review it has and has not had, and say who
is accountable. Prospects in this category are more sceptical than the copy
usually assumes, and candour outperforms reassurance that sounds rehearsed.

## Keeping it fixed

Re-audit when the product changes, when the pharmacy relationship changes, and
when the supply position of the approved product changes, because copy written
against one set of circumstances quietly becomes wrong when they move. Put a
date on the allowlist and a calendar reminder against it. That is the whole
maintenance burden, and it is smaller than one round of correspondence with a
reviewer.

## Frequently asked questions

### Can I say my compounded product contains FDA-approved ingredients?

It is a formulation built to be read as an approval claim, and an approval claim of some form is one of the violations cited most often across the FDA warning letters in our index. The safe position is to describe the active ingredient without attaching approval language to the compounded preparation.

### Can I compare my price to the brand-name drug?

Comparative pricing against a named brand carries an equivalence implication even when the text does not state one, and a misleading comparison is among the violations our index of FDA warning letters records most often. If you compare anything, compare your own service and your own plans.

### Are affiliate and influencer claims my problem?

Practically, yes. Content that drives into your funnel forms part of your marketing surface, and both a certification reviewer and a regulator can reach it. Brands that do not supply affiliates with a claims allowlist inherit whatever the affiliate writes.

## Disclaimer

LegitScript is a trademark of LegitScript LLC. VeriScripts is an independent application-preparation service. It is not affiliated with, endorsed by, or certified by LegitScript LLC, and claims no sponsorship or partnership with it. We prepare, submit, and manage the application; LegitScript alone decides whether certification is granted. "LegitScript" is used here only to name the certification these applications are for.